Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence The therapeutic landscape of IgA nephropathy (IgAN) has evolved rapidly. The renaissance for the treatment of IgAN began with the development of nefecon, targeted-release budesonide (TRF-budesonide; T...

Also see: editorial from Heather Reich and @kdjhaveri.bsky.social in @kireports.bsky.social synthesizing the data on enteric coated budesonide

www.kireports.org/article/S246...

Nothing special about Nefecon IMO (like ACTHAR!)

#NephSky

Renal Physicians Association Annual Meeting: Q&A With the Program Chair | Docwire News Nephrology Times spoke to Katherine Kwon, program chair of the Renal Physicians Association 2026 Annual Meeting, about what the event offers nephrology professionals.

🔗 www.docwirenews.com/post/renal-p...
Attending the Renal Physicians Association Annual Meeting later this month? in this Q&A, program chair Dr. Katherine Kwon explains why it's one you don't want to miss. #nephrology #nephsky

Simplifying the Approach to Primary Aldosteronism • Review the pathophysiology of primary aldosteronism (PA). • Demonstrate that PA is common, and can be found in patients across the entire spectrum of hypertension. • Show th

Please consider joining me on Friday, Apr 10 at 3PM EST for this webinar on Simplifying the Approach to Primary Aldosteronism. #nephsky #htn
www.labroots.com/webinar/simp...

🔗 www.docwirenews.com/journal/apri...
NO FOOLING ... Our April issue is here, featuring AI in kidney care, a Q&A with the new president of ANNA, research updates, and much more. #nephrology #nephsky

The most classic #nephsky #nephmadness month of all is here…. & coincidentally, the most popular pick for @nephmadness.bsky.social champion is in fact, B-cell targets… over 400 brackets!, 🤓😃😅🙏
cc: @lauraratcliffe7.bsky.social

This is no April Fool's joke - SCM26 is 35 days away! 😧

Join us in New Orleans for the latest in nephrology! Register today, with added value available for NKF Professional Members!

Secure your spot: bit.ly/4j9Nxa0

#NKFClinicals #Nephrology #KidneyHealth #NephSky

🚨🚨🚨It is official!!!
Team Cat 🐈 has just won #NephMadness 2026 in the greatest upset of all time!!!
#NephSky

(April Fools)

WCN26-2413 SYNERGISTIC EFFECTS OF TRF-BUDESONID AND SPARSENTAN IN IGA-NEPHROPATHY Sparsentan has emerged as a promising therapeutic option for IgA nephropathy (IgAN) while Targeted-release formulation (Trf-) Budesonid is an established treatment for patients with persistent protein...

This is not at all surprising, and it lends support for other combination therapies that have different mechanisms of action and targets. www.kireports.org/article/S246...

#NephSky #IgANephropathy #IgAN

What Did FDA Find? After reviewing postmarketing data from the applicant's submission (cases from their global safety database), the literature, and the FDA Adverse Event Reporting System (FAERS) database, which has been incorporated into the FDA Adverse Event Monitoring System (AEMS) database, through October 9, 2024, FDA identified 76 cases of DILI with reasonable evidence of a causal association with avacopan use. A total of 74 cases reported a serious outcome, including hospitalization (n=54) and death (n=8). A total of 60 cases provided laboratory information to determine the initial pattern of liver injury; the majority (n=38) had a cholestatic or mixed pattern often marked by substantial elevations in ALP and total bilirubin. A total of 73 cases provided In time from avacopan initiation to DILI onset, and the median time-to-onset was 46 days (range 22 to 140 days). Most cases (n=66) were reported from Japan, followed by the United States (n=5), Europe (n=4), and Canada (n=1). Of the 76 cases, 7 reported biopsy-confirmed VBDS as a complication of DILI with reasonable evidence of a causal association with avacopan use. All cases reported hospitalization (n=7), of which 3 had a fatal outcome. The initial pattern of liver injury was cholestatic or mixed in 4 cases and hepatocellular in 3 cases. The median time from avacopan initiation to DILI onset among the 7 cases was 46 days (range 33 to 59 days). Cases were reported from Japan (n=6) and Canada (n=1). FDA is continuing to monitor postmarketing cases of DILI, including VBDS, involving avacopan and will provide updates as appropriate

More badness uncovered here - today’s FDA warning

Some fatal case of DLI and several VBDS
They are recommending more frequent LFTs while starting Avacopan

www.fda.gov/media/191708...

This does not look good!

#NephSky

Need a place to stay for SCM26? Book your reservation at the Sheraton New Orleans or New Orleans Marriott - now with more rooms available!

Learn more about SCM and the available hotels here: www.kidney.org/spring-clini...

#NKFClinicals #NephSky

Shankland Lab members

The UW Department of Medicine, Division of #Nephrology, has an outstanding opportunity for a full-time, temporary Research Consultant in the highly regarded Shankland Lab!! 🔬 🫘 #research #kidneys #nephsky
@uwdeptmedicine.bsky.social

wd5.myworkdaysite.com/recruiting/u...

#MarchMadness #Nephsky

Conventional cytotoxic chemotherapy-associated nephrotoxicity The sub-field of onco-nephrology has rapidly grown with the proliferation of highly effective cancer therapies and the remarkable improvement in patient survival. Conventional cytotoxic chemotherapy…

Conventional cytotoxic chemotherapy-associated nephrotoxicity
#nephsky

#NephMaddness #NephSky Are you ready for some #BleRibbonFail 😂😂😂

NephJC Covers LBCTs at the World Congress — NephJC The NephJC editors cover the simultaneous publication from the world congress

Covering the world 🌐 @hswapnil.medsky.social @nephroseeker.medsky.social
🧑‍💻Reporting in from Yokohama, Japan #ISNWCN 🌸
📰Read all about the late breaking news #NephJC #NephSky
www.nephjc.com/news/isnwcn-yokohama

Techniques to predict survival outcomes in nephrology: basics and traditional methods Predicting survival outcomes is one of the most crucial tasks that nephrologists face. On an individual level, predicted survival times affect all aspects of decision-making, including the initiation…

Techniques to predict survival outcomes in nephrology: basics and traditional methods
#nephsky
#biostats

Did you know that the “four-hit” hypothesis for IgA nephropathy #IgAN was first clearly articulated by Hitoshi Suzuki et al. in their 2011 J. Am. Soc. Nephrol. paper, “The pathophysiology of IgA nephropathy.”
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/21949093/

Reduced podocyte stiffness is a feature of proteinuric kidney disease Proteinuria is a common and important manifestation of glomerular injury. Although the molecular events driving proteinuria have been studied extensively, the biomechanical changes that occur in the…

Reduced podocyte stiffness is a feature of proteinuric kidney disease
#nephsky

Therapeutic targets 🎯and positioning of treatments in IgA nephropathy 🔬 #IgAN ca. 2026 from @kidneyint.bsky.social
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41895685/

Dogs versus cats may be the toughest choice this #NephMadness
Have you turned in your brackets yet #NephSky #MedSky ?

Cancer Therapy and the Kidney The rapid evolution of anti-cancer therapies has significantly improved outcomes for patients with malignancies. However, these advances have also been accompanied by a rise in nephrotoxicity…

Review: Cancer Therapy and the Kidney
#nephsky

PISCES: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis ca. 2026 from @nejm.org
@asnkidney.bsky.social
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41201837/
👉 www.kidneynews.org/view/journal...

Unique aspects of the acute kidney injury associated with infections in the tropics: presentation, challenges and opportunities “The tropics” currently account for around 40% of the world’s population and face unique environmental challenges with limited resources, a deficient health system, a rudimentary sanitary…

Review: Unique aspects of the acute kidney injury associated with infections in the tropics: presentation, challenges and opportunities
#nephsky

Hi, I’m Sruthi, Nephrologist from Kerala, India.
I’m into clinical medicine, research, and lately curious about AI.
Outside work, I enjoy time with family, art, and real conversations.
Here to learn, connect, and grow 🙂
#Nephsky #Nephbluesky #Medsky

Bx for pt with AKI and nephrotic range proteinuria. Hx of IV drug abuse (with skin popping), and chronic staph infections. AA amyloidosis was the unsurprising finding. #renalpath #pathsky #nephsky

There’s still time!
Turn in your #NephMadness 2026 brackets!! 🏀
#NephSky #MedSky
No bias here 😜@nephropocus.bsky.social

Perrault Syndrome Unmasked: Genomic Reclassification of a Fabry-Like CKDx Phenotype A 30-year-old female was admitted to the nephrology ward for the evaluation of chronic kidney disease (CKD) of unexplained cause (CKDx), initially raising concern for Fabry disease. She had…

Case report: Perrault Syndrome Unmasked: Genomic Reclassification of a Fabry-Like CKDx Phenotype
#nephsky

Efficacy and Safety of Atrasentan in Patients with #IgAN Receiving Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) ca. 2026 from @asnpublications.bsky.social
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky

Photo Credit: @nephroseeker.medsky.social

👉 journals.lww.com/jasn/fulltex...

Trying to catch up with #IgAN trials⁉️

Check out 👉 “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social @haresh11.bsky.social @alexgr23.bsky.social @saynanorouzi.bsky.social
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41050133/

SGLT2 inhibition: Pleiotropic direct cardiac and kidney effects ⁉️
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/35589167/